This review synthesizes recent data, detailing the mechanism by which cellular senescence (CS) promotes Alzheimer's disease (AD) progression, and also considers the potential of targeting senescent cell removal as a treatment option for Alzheimer's Disease.A collection of diseases, termed channelopathies, originate from either a reduction in ion channel cell surface expression or the failure of these ion channels to function properly. To effectively manage the underlying cause, the delivery and incorporation of a functional ion channel into the membrane of the target cell is required. Regrettably, for the majority of channelopathies, the current treatment regimens are unfortunately limited to alleviating symptoms, with therapies capable of addressing the fundamental damage still absent. Gene and protein therapies are the requisite approaches in this context. Gene therapy's success in expressing a functional protein is contingent upon the diseased cell's proper folding and membrane transport of the protein. Protein therapy, while promising direct delivery of a functional protein, hinges on a purification process that doesn't compromise protein function, coupled with a suitable, targeted delivery vehicle. An overview of channelopathies and their symptomatic treatments is offered in this review. A consideration of gene therapy strategies, mainly using viral vectors, is undertaken, moving on to the role nanomedicine plays in protein therapy and its possible use for delivering functional ion channels to diseased cells.The leading cause of morbidity and mortality in Western societies, despite significant progress in primary and secondary prevention, is coronary artery disease (CAD). Henceforth, a number of novel biomarkers have emerged as promising diagnostic and therapeutic targets, which could yield improved outcomes, even if conventional risk factors are properly managed. Lp(a), lipoprotein (a), displays a pro-atherogenic, pro-thrombotic, and pro-inflammatory profile, with its concentration remaining fairly consistent and influenced by genetic predisposition. Numerous epidemiological studies have shown a positive association between high levels of Lp(a) and an elevated risk of acute coronary syndromes (ACS), even after adjusting for other risk factors for coronary artery disease in statistical models. Until recently, therapeutic options for Lp(a) were absent, leading to Lp(a)'s current status as a risk and treatment-modifying biomarker. Current guidelines recommend intensified low-density lipoprotein (LDL) treatment strategies for patients with elevated Lp(a) levels and intermediate-to-high risk. Innovative treatment strategies for Lp(a) have surfaced, including antisense oligonucleotides and small interfering RNAs, leading to a substantial decline in Lp(a) levels. The ongoing phase-3 trials' conclusions will answer the question of whether Lp(a) merits specific biomarker treatment to mitigate cardiovascular mortality. The current evidence concerning Lp(a) as a biomarker for CAD risk, along with future prospects of pharmaceutical approaches to lower Lp(a) in high-risk patients, is the subject of this review.The study's goal was to ascertain the diagnostic value of circulating neurofilament light chain (NFL) concentrations across various forms of dementia.Earlier research findings regarding blood NFL changes were inconsistent across different forms of dementia, including Alzheimer's disease, frontotemporal dementia, Parkinson's disease dementia, Creutzfeldt-Jakob disease, and Lewy body dementia.By conducting a meta-analysis, the results of studies investigating the diagnostic significance of circulating NFL levels in different forms of dementia were aggregated to fortify the evidence.A search for articles published prior to July 2022, which explored blood NFL levels in dementia, was conducted on the following databases: PubMed, Web of Science, EMBASE, Medline, and Google Scholar. The computed results were obtained using STATA 120 software as a tool.AD patients displayed significantly elevated NFL concentrations in serum and plasma compared to healthy controls, with a standard mean difference of 109, a 95% confidence interval of 0.48-1.70, an I2 of 974%, and a p-value less than 0.0001. Neurofilament light chain (NFL) concentrations in serum and plasma were significantly associated with reduced cerebrospinal fluid (CSF) A1-42 levels, elevated CSF total tau (t-tau), increased CSF phosphorylated tau (p-tau), decreased Mini-Mental State Examination (MMSE) scores, and diminished memory in AD patients. Furthermore, individuals with mild cognitive impairment (MCI) exhibited elevated neurofilament light chain (NFL) concentrations in both serum and plasma when compared to healthy controls (SMD = 0.53, 95% CI 0.18, 0.87, I² = 93.8%, p < 0.0001). In MCI patients, NFL levels found in serum and plasma displayed no noteworthy association with memory and visuospatial function. In the analysis comparing preclinical Alzheimer's Disease (AD) and healthy controls (HC), no significant difference emerged. The standardized mean difference (SMD) was 0.18, the 95% confidence interval was -0.10 to 0.47, the I² was 0.00%, and the p-value was 0.438. In both serum and plasma, FTD patients exhibited significantly higher NFL levels when compared to healthy controls, with a statistically powerful result (SMD = 108, 95% CI 072, 143, I2 = 833%, p < 0001). Elevated NFL levels in blood (serum and plasma) exhibited a positive association with increased NFL concentration in cerebrospinal fluid (CSF) in frontotemporal dementia cases. The pooled analysis produced the following parameter estimates: sensitivity, 0.82 (95% confidence interval, 0.72 to 0.90); and specificity, 0.91 (95% confidence interval, 0.83 to 0.96). Compared to healthy controls (HC), CJD patients exhibited a rise in NFL concentrations within their serum and plasma. Serum and plasma NFL levels exhibited no notable disparity between AD and FTD groups (SMD = -0.003, 95% CI -0.77 to 0.72, I² = 833%, p = 0.003).The study, in its conclusion, revealed abnormal blood NFL levels in AD and MCI, but not in subjects with preclinical AD. The presence of abnormal NFL levels in the blood was evident in both FTD and CJD cases.The study's overall conclusion was that unusual blood NFL levels were detected in AD and MCI, but not in preclinical AD stages. Abnormal blood NFL levels were observed in both FTD and CJD cases.Recurring episodes of a dermatological ailment, driven by an autoimmune response, define psoriasis. This autoimmune skin condition, a prevalent issue, impacts 2-3% of individuals globally. This current review strives to examine and assess the effectiveness of established and cutting-edge nanotechnological strategies in alleviating psoriasis, and to discuss potential future directions. A comprehensive search of diverse electronic databases, encompassing ScienceDirect, Scopus, Google Scholar, ClinicalTrials.gov, Google Patents, ResearchGate, and PubMed, furnished the entirety of the data supporting this review article concerning psoriasis management through various anti-psoriatic agents and nanotechnology strategies. A study encompassing keywords like topical delivery, liposomes, niosomes, microneedles, clinical trials, patents, disease mechanisms, biosimilars, cytokines, and other pertinent terminology was undertaken. Nano-technological approaches are rising in significance due to their capacity for precise delivery, rapid therapeutic effects, and minimized systemic impact. To address psoriatic conditions, researchers have examined innovative, secure, and efficient alternative therapeutic approaches. Besides this, the prospective part played by numerous conventional psoriasis remedies has been explored in detail. Extensive exploration has been undertaken of patents, either granted or pending, focusing on topical treatments for psoriasis. Advanced nanotechnology has enabled pharmaceuticals to exhibit enhanced physical, chemical, pharmacokinetic, and pharmacodynamic properties. Despite the considerable research undertaken, a full eradication of psoriasis proves challenging. An in-depth examination of the literature indicates that novel nanoparticle-based delivery approaches may augment pharmacological efficacy and eliminate or resolve issues linked to this ailment. A thorough review of the various drug delivery systems for treating psoriasis, including the different stages of clinical trials, patent status, therapeutic molecule commercialization, and future research prospects, has been undertaken.A clear health concern for Asian-Pacific and developing nations is HFMD, a noticeable disease prevalent among children typically under five. It is often the case that enterovirus 71 (EV71) and Coxsackievirus A16 are the causative agents behind this disease. HFMD presents as a mild fever and general illness, with the symptoms typically lasting about 10 days. Young males, poor hygiene, and a high number of social contacts are identified as possible risk elements. Identifying HFMD clinically involves isolating the virus from the patient's stool and throat, and then visually confirming it under a light microscope. The Polymerase Chain Reaction Assay is employed as the gold standard method for diagnosing viral infection from swabbed lesions. A delayed confirmation of the matter might produce intricate complications. Treatment and vaccination options for the various forms of hand, foot, and mouth disease are not yet widely available and licensed for general use. Implementing the eight guidelines set forth by the WHO is the principal approach to curbing and preventing this disease from spreading.Avian spirochetosis, an acute bacterial infection in birds, is disseminated by ticks. Symptoms associated with clinical conditions show considerable variation and are frequently nonspecific in nature. TNF-alpha signal Only through the detection of the infectious spirochete can a precise diagnosis of the condition be made.